Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL)

Journal of Patient-Reported Outcomes

Table 3 Comparisons of the global CVID_QoL scores for the Norwegian and the Italian [8] cohort

Characteristics	Global CVID_QoL scores, mean (SD)
Characteristics	Norway N = 83	Italy [8] N = 118	p - value*
Total	37.4 (15.3)	29 (16.5)	< 0.001
Male	33.8 (14.4)	25.7 (14.2)	< 0.05
Female	38.6 (15.6)	31.3 (16.4)	< 0.05
Age ≤ 50 years	37.7 (17.9)	26.5 (15.5)	< 0.001
Age > 50 years	37.1 (11.8)	32.6 (15.7)†	ns
Education ≤13 years	37.6 (18.8)	32.1 (17.5)	ns
Education > 13 years	37.2 (12.1)	28.3 (15.3)	< 0.001
No children < 18 years	36.4 (14.7)	NA
Children < 18 years	41.3 (16.8)	NA
CVID	36.6 (15.3)	29 (16.5)	< 0.05
Other PAD	38.8 (15.5)	NA
SCIG**	41.1 (15.7)	NA
IVIG**	34.5 (13.5)	NA
BMI ≤ 18.5	39.3 (3.0)	41.1 (11.4)‡	ns
BMI 18.6–24.9	37.0 (16.2)	28.2 (15.8)	< 0.05
BMI ≥ 25	35.5 (15.2)	28.0 (15.9)	ns

CVID_QoL scores are presented as mean (SD). NA = not available, ns = not significant, CVID = common variable immunodeficiency, PAD = primary antibody deficiency, SCIG = subcutaneous immunoglobulin, IVIG = intravenous immunoglobulin, BMI=Body mass index.*Comparison of Global CVID_QoL scores between the Norwegian and the Italian cohorts.**Data only available for the patients recruited through the CRD seminar (n = 32).†Reported as significantly different from age ≤ 50 years (p = 0.04) in Quinti et al. [8].‡Reported as significantly different from BMI > 18.5 (p = 0.02) in Quinti et al. [8]. Otherwise, no significant differences were found for the global CVID_QoL scores within the Italian or Norwegian cohorts